Skip to content
10-Q

Quarterly Report

CASI PHARMACEUTICALS, INC.

0001558370-22-017615

← back to feed
Filed
Nov 14, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Nov 8, 2022 13.61M sh
Shares Diluted Q3 2022 · Sep 30, 2022 13.61M sh
Shares Diluted Q3 2022 · Sep 30, 2022 13.67M sh
Shares Diluted Q3 2022 · Sep 30, 2021 13.98M sh
Shares Diluted Q3 2022 · Sep 30, 2021 13.49M sh
Stock Repurchased Q3 2022 · Sep 30, 2022 $3M
Capex Q3 2022 · Sep 30, 2022 $2.19M
Capex Q3 2022 · Sep 30, 2021 $3.73M
Operating Cash Flow Q3 2022 · Sep 30, 2022 −$20.25M
Operating Cash Flow Q3 2022 · Sep 30, 2021 −$19.2M
Short Term Debt Q3 2022 · Sep 30, 2022 $3M
Short Term Investments Q3 2022 · Sep 30, 2022 $6.31M
Short Term Investments Q3 2022 · Dec 31, 2021 $9.87M
Cash And Equivalents Q3 2022 · Sep 30, 2022 $26.74M
Cash And Equivalents Q3 2022 · Dec 31, 2021 $38.7M
Cash And Equivalents Q3 2022 · Sep 30, 2021 $53.13M
Stockholders Equity Q3 2022 · Sep 30, 2022 $61.71M
Stockholders Equity Q3 2022 · Jun 30, 2022 $66.94M
Stockholders Equity Q3 2022 · Mar 31, 2022 $74.99M
Stockholders Equity Q3 2022 · Dec 31, 2021 $84.5M
Stockholders Equity Q3 2022 · Sep 30, 2021 $86.61M
Stockholders Equity Q3 2022 · Jun 30, 2021 $94.8M
Stockholders Equity Q3 2022 · Mar 31, 2021 $100.03M
Stockholders Equity Q3 2022 · Dec 31, 2020 $81.54M
Current Liabilities Q3 2022 · Sep 30, 2022 $29.75M
Current Liabilities Q3 2022 · Dec 31, 2021 $13.19M
Total Liabilities Q3 2022 · Sep 30, 2022 $44.69M
Total Liabilities Q3 2022 · Dec 31, 2021 $30.34M
Current Assets Q3 2022 · Sep 30, 2022 $55.61M
Current Assets Q3 2022 · Dec 31, 2021 $61.97M
Total Assets Q3 2022 · Sep 30, 2022 $127.91M
Total Assets Q3 2022 · Dec 31, 2021 $138.3M
Eps Diluted Q3 2022 · Sep 30, 2022 −$0.38
Eps Diluted Q3 2022 · Sep 30, 2022 −$1.57
Eps Diluted Q3 2022 · Sep 30, 2021 −$0.73
Eps Diluted Q3 2022 · Sep 30, 2021 −$2.30
Eps Basic Q3 2022 · Sep 30, 2022 −$0.38
Eps Basic Q3 2022 · Sep 30, 2022 −$1.57
Eps Basic Q3 2022 · Sep 30, 2021 −$0.73
Eps Basic Q3 2022 · Sep 30, 2021 −$2.30
Sga Expense Q3 2022 · Sep 30, 2022 $4.85M
Sga Expense Q3 2022 · Sep 30, 2022 $15.69M
Sga Expense Q3 2022 · Sep 30, 2021 $5.26M
Sga Expense restated Q3 2022 · Sep 30, 2021 $16.25M
Net Income Q3 2022 · Sep 30, 2022 −$5.2M
Net Income Q3 2022 · Sep 30, 2022 −$21.48M
Net Income Q3 2022 · Jun 30, 2022 −$7.68M
Net Income Q3 2022 · Mar 31, 2022 −$8.6M
Net Income Q3 2022 · Sep 30, 2021 −$10.22M
Net Income Q3 2022 · Sep 30, 2021 −$31.05M
Net Income Q3 2022 · Jun 30, 2021 −$6.95M
Net Income Q3 2022 · Mar 31, 2021 −$13.88M
Operating Income Q3 2022 · Sep 30, 2022 −$6.35M
Operating Income Q3 2022 · Sep 30, 2022 −$21.39M
Operating Income Q3 2022 · Sep 30, 2021 −$6.89M
Operating Income Q3 2022 · Sep 30, 2021 −$30.47M
Gross Profit Q3 2022 · Sep 30, 2022 $5.97M
Gross Profit Q3 2022 · Sep 30, 2022 $16.29M
Gross Profit Q3 2022 · Sep 30, 2021 $4.7M
Gross Profit Q3 2022 · Sep 30, 2021 $12.25M
Cost Of Revenue Q3 2022 · Sep 30, 2022 $4.25M
Cost Of Revenue Q3 2022 · Sep 30, 2022 $11.56M
Cost Of Revenue Q3 2022 · Sep 30, 2021 $3.42M
Cost Of Revenue Q3 2022 · Sep 30, 2021 $8.76M
Revenue Q3 2022 · Sep 30, 2022 $10.21M
Revenue Q3 2022 · Sep 30, 2022 $27.79M
Revenue Q3 2022 · Sep 30, 2021 $8.08M
Revenue Q3 2022 · Sep 30, 2021 $20.9M
Stock Issued Q3 2022 · Mar 31, 2022 2.54M sh